We are enclosing Audited Financial Results for the Quarter ended 31st march , 2026 which are approved in Board Meeting which was held today i.e Wednesday, 27th Day of May, 2026

Revenue DeclinePat NegativeNegative Operating CashflowRelated Party TransactionsResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.2%Reaction day

₹129.95

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.6%-1.6% vs market

Pharmaceuticals peers, median of 162sector-0.5%-1.8% vs sector

On the reaction day the stock moved 1.6 pts less than Nifty Microcap 250 and 1.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.2-0.6-1.6-0.5-1.8

Next day

-4.6-1.7-2.9-1.2-3.4

-5.3-0.7-4.7-1.5-3.9

-5.3-0.4-4.9-1.6-3.8

-6.1+0.4-6.6-1.1-5.0

-3.8+0.4-4.2-1.3-2.5

-1.5+0.3-1.8-0.7-0.8

15d

-8.4+5.5-13.9+1.3-9.7

-9.4+4.6-14.0+2.6-11.9

-15.6+5.3-20.9+5.3-20.9

-24.6+11.6-36.1+6.9-31.5

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 162Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Godavari Drugs Limited reported audited FY26 results with revenue declining 6.7% to ₹10,580.81 Lakhs from ₹11,335.01 Lakhs in FY25. Net profit fell 6.6% to ₹408.91 Lakhs from ₹438.00 Lakhs, with basic EPS at ₹5.43 vs ₹5.82 prior year. The company raised ₹4,411.73 Lakhs via preferential allotment in March 2026, which was fully deployed towards capital expenditure for pharmaceutical manufacturing expansion (₹1,000 Lakhs), working capital (₹1,711.73 Lakhs), and repayment of promoter/director unsecured loans (₽1,600 Lakhs). Operating cash flow sharply deteriorated to ₹73.36 Lakhs from ₹1,119.60 Lakhs in FY25. Inventories increased to ₹4,606.41 Lakhs from ₹2,794.13 Lakhs. Related party transactions totaling ₹376.32 Lakhs included loans to directors (₹273 Lakhs), remuneration, rent, and interest payments. Statutory auditors M/s Ayyadevara & Co. issued an unmodified (clean) opinion.

Likely market impact

Revenue and profit decline along with sharply reduced operating cash flow are concerning for shareholders, though the clean audit opinion and successful capital raise for expansion provide some support. The company appears to be in an investment phase with significant inventory buildup and working capital deployment.